The reimbursement of emerging durable/potentially curative cell and gene therapies is likely to be a challenge for the US healthcare market. Considering the pricing of cell- and gene-based therapies approved … Read More
FoCUS responds to HHS “Blueprint” Request for Information
Federal initiative seeks to make access to innovative therapies wider and more financially sustainable On May 16, 2018 the US Department of Health and Human Services (HHS) published a … Read More
Stop-Loss Insurance or Reinsurance for Multiyear Contracts
In previous Research Briefs, we have discussed challenges faced by payers when contemplating using multiyear performance-based contracts. In this brief, we extend the discussion to include additional difficulties that may … Read More
Impact of Patient Mobility on Annuity/Performance-Based Contracting
Spreading payments over time for durable or curative therapies can provide a better alignment between benefits and costs, but creates challenges when patients switch insurance coverage during the contract term. … Read More
Orphan Reinsurer Benefit Managers (ORBMs)
An Orphan Reinsurer Benefit Manager (ORBM) could address the financial challenges (payment timing, therapeutic performance risk, actuarial risk), created by durable/potentially curable gene and cell therapies especially for smaller insurers … Read More
PPD, Evidera join NEWDIGS Initiative at MIT as a Strategic Partner
Collaboration to drive innovation across health care ecosystem WILMINGTON, N.C., May 22, 2018– Pharmaceutical Product Development, LLC (PPD), and its real-world research and market access business unit, Evidera, have joined the Massachusetts Institute … Read More
NEWDIGS in the world, May 2018
NEWDIGS leadership and thinking at recent international gatherings Gigi Hirsch and R. John Glasspool at LIGHT 2018 The second annual LIGHT Forum (Leaders in Global Healthcare and Technology) took place … Read More
Precision Financing strategies explored in FoCUS Design Lab
Healthcare innovation stakeholders co-develop solutions to make curative therapies accessible to patients, propose new pilot project CAMBRIDGE, MASSACHUSETTS—The NEWDrug Development ParadIGmS (NEWDIGS) initiative at the MIT Center for Biomedical Innovation (CBI) hosted … Read More
Impact of Actuarial Risk on Health Plans
The uncertain number of patients likely to be treated with an expensive novel therapy (actuarial risk) could represent a major financial issue for some payers. In this brief, we will … Read More
FoCUS Project: Recent International Event Highlights (April 2018)
NEWDIGS FoCUS project leaders have appeared in three recent meetings to share emerging perspectives on financing potentially durable but expensive new therapies. Casey Quinn and R. John Glasspool speak at … Read More